Overview

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Antibodies
Pembrolizumab